Australia’s building new partnerships to strengthen our shared regional #healthsecurity. With @APCOVE, @MenziesResearch & @MedicinesDev, we’re supporting countries to strengthen #OneHealth monitoring, prevent outbreaks, and develop new treatments for neglected tropical diseases.
@MectizanMDP@Sightsavers MDGH congratulates @MectizanMDP upon reaching this impressive milestone, not just counting the years of dedication, but the countless lives impacted. You have long been our inspiration #endNTDs
Medicines Development for Global Health congratulates Founder and Managing Director Mark Sullivan on being named to the 2022 PharmaVoice 100 list of top industry leaders. Read more: https://t.co/DsPKQqR9tH
@MedicinesDev acknowledges the Australian NGO Cooperation Program and @FredHollows for their assistance to #Vanuatu in the successful efforts to eliminate trachoma as a public health problem. https://t.co/PoyohICfYQ
Vanuatu validated by @WHO for eliminating trachoma as public health problem. It's the 1st country in Pacific Islands, the 4th @WHOWPRO country and 14th country globally to achieve this milestone. Congrats to all on this great success. #Vanuatu! #beatNTDs#NTDRoadmap2030
Leading 🇦🇺 voices have written to @ScottMorrisonMP calling for:
🌏$250m to COVAX to tackle global vaccine inequity
👩⚕️$50m to address hesitancy in our region
🦠$100m to CEPI to reduce future pandemics
Open Letter - https://t.co/FgSkYMrfRB
#EndCOVIDforAll#auspol
MDGH is proud to be a partner for #WorldNTDDay – Sunday January 30, 2022. Visit our website to learn more about our mission to develop new medicines for several of these important NTDs. https://t.co/SrqftfEYMF
Mark Sullivan, Founder of MDGH has been awarded Officer of the Order of Australia (AO), one of highest civilian honours in Australia. Mark was recognised “for distinguished service to medical research, to business, and to education”
Read more: https://t.co/mJ6rRWj8y1
Join MDGH at #TropMed21 virtual meeting this week, delivering 2 presentations at symposium on clin development of new treatments to eliminate onchocerciasis, and early results from open label study to find optimal dose of moxidectin in children aged 4-11. https://t.co/lLT8TajLbc
MDGH is pleased to announce treatment of first enrollees in 3 key clinical trials of #moxidectin in #onchocerciasis co-funded by @EDCTP: repeat dose implementation study; single-dose implementation safety study; pediatric dose-finding study #endNTDs. https://t.co/e1OBv0OOtc
Our annual report is now published. Find out more about our accomplishments from 2020 and our development plans for #moxidectin and CC-11050. Much work remains to be done to #endNTDs and #endTB.
Download here: https://t.co/cIIFkc7vvG
Results from a dose-ranging Phase 2a study of #moxidectin in #Strongyloides stercoralis infection in adults recently published in Lancet Infectious Diseases. #endNTDs https://t.co/eTf1fmqVEd
#TB is a major cause of ill health and one of the top 10 causes of death worldwide: 2B people have latent infection and, in 2019 alone, 1.4M died. TB is a pandemic that has been with us for thousands of years and we're still fighting it. #endTB#WorldTBDay#theclockisticking
“[W]e urge the world to look at how we’ve responded to #COVID19 and imagine – and fight for – a world where all disease threats are treated with urgency commensurate with the devastation that they wreak.” – Willo Brock, Andrea Lucard and Mark Sullivan
https://t.co/rMCq7m1a85
We’re proud to acknowledge the 6th UN International Day of Women and Girls in Science: 78% of our team at @MDGH are #WomeninSTEM, developing medicines and vaccines for people who need them most. We’re pleased to introduce you to some of our senior scientists: